Insider Buying: Perspective Therapeutics, Inc. (NYSE:CATX) CEO Purchases 14,500 Shares of Stock

Perspective Therapeutics, Inc. (NYSE:CATX) CEO Johan M. Spoor acquired 14,500 shares of the firm’s stock in a transaction that occurred on Monday, November 25th. The shares were purchased at an average price of $3.78 per share, with a total value of $54,810.00. Following the acquisition, the chief executive officer now owns 152,072 shares of the company’s stock, valued at approximately $574,832.16. This trade represents a 10.54 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Perspective Therapeutics Trading Up 6.3 %

Shares of CATX stock opened at $3.69 on Tuesday. The company has a fifty day simple moving average of $11.33. Perspective Therapeutics, Inc. has a 1 year low of $2.28 and a 1 year high of $19.05.

Perspective Therapeutics (NYSE:CATX) last released its earnings results on Tuesday, November 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.21). Perspective Therapeutics had a negative return on equity of 27.40% and a negative net margin of 4,096.66%. The business had revenue of $0.37 million for the quarter. Research analysts expect that Perspective Therapeutics, Inc. will post -0.86 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in CATX. The Manufacturers Life Insurance Company grew its stake in shares of Perspective Therapeutics by 8.9% in the third quarter. The Manufacturers Life Insurance Company now owns 20,514 shares of the company’s stock valued at $274,000 after buying an additional 1,672 shares in the last quarter. Sykon Capital LLC lifted its stake in Perspective Therapeutics by 4.7% in the second quarter. Sykon Capital LLC now owns 37,932 shares of the company’s stock valued at $378,000 after acquiring an additional 1,717 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Perspective Therapeutics by 5.8% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 58,678 shares of the company’s stock valued at $783,000 after acquiring an additional 3,211 shares during the period. US Bancorp DE increased its stake in shares of Perspective Therapeutics by 142.7% during the 3rd quarter. US Bancorp DE now owns 6,576 shares of the company’s stock worth $88,000 after purchasing an additional 3,866 shares during the last quarter. Finally, nVerses Capital LLC bought a new stake in shares of Perspective Therapeutics in the 3rd quarter valued at about $57,000. Institutional investors and hedge funds own 54.66% of the company’s stock.

Analyst Ratings Changes

CATX has been the topic of a number of recent analyst reports. UBS Group began coverage on shares of Perspective Therapeutics in a research report on Thursday, October 24th. They set a “buy” rating and a $20.00 price target on the stock. Bank of America lowered Perspective Therapeutics from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $24.00 to $5.00 in a report on Monday. Royal Bank of Canada lowered their price target on Perspective Therapeutics from $25.00 to $16.00 and set an “outperform” rating for the company in a report on Monday. Truist Financial assumed coverage on shares of Perspective Therapeutics in a research report on Wednesday, September 25th. They issued a “buy” rating and a $21.00 price objective on the stock. Finally, Oppenheimer cut their price target on Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating on the stock in a report on Friday. One analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $15.14.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.